Grantopen🌐 United StatesPAR-25-051

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)

National Institutes of Health

Details?

Posted: Sep 25, 2024
Response deadline: Aug 18, 2026, 12:00 AM UTC (37d)
Type: Grant
Category: 93.121, 93.867, 93.279, 93.853, 93.242, 93.273, 93.213, 93.866
Status: open
Buyer: National Institutes of Health
Department: HHS-NIH11
Jurisdiction: United States
Reference #: PAR-25-051

Doc Type: synopsis
Opp Status: posted

Similar open solicitations

Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
United States · Oct 1, 2024
NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required)
United States · Nov 7, 2024
BRAIN Initiative: Clinical Studies to Advance Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UH3 Clinical Trial Optional)
United States · Nov 5, 2024
Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)
United States · May 4, 2026
National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U01 Clinical Trial Optional)
United States · Jan 15, 2025
BRAIN Initiative: Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Optional)
United States · Nov 5, 2024

Similar past solicitations

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
United States · Nov 1, 2023
Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
United States · Oct 1, 2024
Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional)
United States · Nov 6, 2024
Development of Medications to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
United States · Jan 3, 2025
Enhancing Blueprint Transformation Network Capacity: Workforce Support and System Development through Clinical Knowl
Vermont · May 19, 2026

Finding similar opportunities…

This listing is a summary from United States's open procurement data. We ingest every field the feed publishes; the full solicitation documents are on the source portal.